Ensuring Digital Health Standards
BioSpectrum Asia|June 2022
The use of digital health (DH) has grown rapidly over the last couple of years - accelerating even more during the COVID-19 pandemic. As DH becomes part of the traditional healthcare system, it's important to have stringent regulations and higher levels of scrutiny. Regulators around the world and in Asia are realising this fact and changing regulations accordingly. Let's look at the regulatory landscape in APAC.
Ayesha Siddiqui
Ensuring Digital Health Standards

Digital health devices and applications pose unique challenges to regulators, and the agencies are getting serious about meeting them. Within a region as diverse as APAC, with different levels of both healthcare provision and regulatory expertise, there is inevitably a wide variation in how DH solutions are brought to market. Let's look at how countries - Australia, Singapore, Japan, China, Korea, most active in enacting such laws, are establishing regulatory frameworks.

Australia

There is no single legislation which governs digital health technology in Australia. her, different laws govern different aspects of digital health technology. In Australia, the main legislation in relation to digital health technology falls into three categories: therapeutic goods law (TGA), consumer protection law and privacy law. The TGA regulates medical devices, including software as a medical device, such as software that uses information about symptoms to make a diagnosis, and mobile apps coupled with devices for calculating medication dosages.

The TGA Act was updated in August 2021 to address the increase in medical related software-based products being developed. The TGA Act includes new classification rules for software-based medical devices, including for those that provide a diagnosis for health conditions, monitor the state of health conditions, specify a treatment or provide therapy. The reforms also amend the "Essential Principles" - the requirements relating to the safety and performance of medical devices - in relation to cyber security, the management of data and information, and requirements relating to development, product and maintenance of medical devices. Digital health technologies that collect personal information also need to comply with Australia's privacy laws as set out in the Privacy Act.

This story is from the June 2022 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

This story is from the June 2022 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

MORE STORIES FROM BIOSPECTRUM ASIAView All
Ushering Fourth Industrial Revolution in Telangana
BioSpectrum Asia

Ushering Fourth Industrial Revolution in Telangana

Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).

time-read
6 mins  |
BioSpectrum Asia April 2024
How Indian Biotech Investments are on a Doubling Spree
BioSpectrum Asia

How Indian Biotech Investments are on a Doubling Spree

A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.

time-read
4 mins  |
BioSpectrum Asia April 2024
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
BioSpectrum Asia

"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”

South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.

time-read
5 mins  |
BioSpectrum Asia April 2024
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
BioSpectrum Asia

"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"

Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.

time-read
4 mins  |
BioSpectrum Asia April 2024
Can Test, Treat, Track Beat Malaria?
BioSpectrum Asia

Can Test, Treat, Track Beat Malaria?

Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.

time-read
8 mins  |
BioSpectrum Asia April 2024
Engineering CAR T cell sharpshooters
BioSpectrum Asia

Engineering CAR T cell sharpshooters

Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.

time-read
6 mins  |
BioSpectrum Asia April 2024
Addressing Challenges in Cell Therapy Manufacturing
BioSpectrum Asia

Addressing Challenges in Cell Therapy Manufacturing

Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.

time-read
2 mins  |
BioSpectrum Asia April 2024
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
BioSpectrum Asia

"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"

Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.

time-read
5 mins  |
BioSpectrum Asia April 2024
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
BioSpectrum Asia

Addressing Accessibility and Affordability of CELL & GENE THERAPIES

Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.

time-read
10+ mins  |
BioSpectrum Asia April 2024
Korea designs sweat resistant wearable robot sensor
BioSpectrum Asia

Korea designs sweat resistant wearable robot sensor

New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.

time-read
1 min  |
March 2024